Skip to content

Advertisement

  • Research
  • Open Access

PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NF-κB/MMP-9 signaling pathway

†Contributed equally
Molecular Cancer201514:66

https://doi.org/10.1186/s12943-015-0332-2

©  Shi et al.; licensee BioMed Central. 2015

  • Received: 17 October 2014
  • Accepted: 3 March 2015
  • Published:

Abstract

Background

PinX1 (PIN2/TRF1-interacting telomerase inhibitor 1) was suggested to be correlated with tumor progression. This study was designed to evaluate the role of PinX1 in human breast cancer.

Methods

To evaluate the function of PinX1 in breast cancer, we used a tissue microarray (TMA) of 405 human breast cancer patients and immunohistochemistry to analyze the correlation between PinX1 expression and clinicopathologic variables and patient survival. We also detected the abilities of cell migration and invasion in breast cancer by performing cell migration and invasion assay, gelatin zymography and western blot analysis. Lastly, we set up the nude mice model by Tail vein assay to exam the functional role of PinX1 in breast cancer metastasis.

Results

We found that low PinX1 expression was associated with lymph node metastasis (P = 0.002) and histology grade (P = 0.001) in patients, as well as with poorer overall and disease-specific survival (P = 0.010 and P = 0.003, respectively). Moreover, we identified that PinX1 inhibited the migration and invasion of breast cancer by suppressing MMP-9 expression and activity via NF-κB-dependent transcription in vitro. Finally, our mice model confirmed that PinX1 suppressed breast cancer metastasis in vivo.

Conclusions

Our data revealed that low PinX1 expression was an independent negative prognostic factor for breast cancer patients. These findings suggested that PinX1 might be function as a tumor metastasis suppressor in the development and progression of breast cancer by regulating the NF-κB/MMP-9 signaling pathway, and might be a prognostic marker as well as a therapeutic target for breast cancer.

Keywords

  • PinX1
  • Breast cancer
  • Metastasis
  • Prognostic
  • NF-κB
  • MMP-9

Introduction

Breast cancer is the most common malignancy of the female, and its survival rate falls from 90% for localized to 20% for metastatic disease [1]. Each year there are approximately 400 000 deaths because of breast cancer [2]. The high mortality is related to complications of tumor dissemination and distant metastasis. Metastasis is a multistep process requiring cell proliferation, migration, invasion, adhesion, vessel formation and colonization to a secondary site [3]. Therefore, interrupting the metastatic process is a key to decreasing breast cancer mortality. Alterations in chromatin play a critical role in breast cancer progression and metastasis, but the exact molecular mechanisms are still limited [4].

Human telomerase is a ribonucleoprotein, mainly consisting of catalytic subunit hTERT and RNA template hTR, which involves in malignant tumor formation [5-7]. Human telomerase reverse transcriptase (hTERT), containing two conserved N-terminal and four C-terminal domains essential for telomerase catalytic activity, is referred as the rate-limiting step of telomerase activation [8]. Telomerase expression is suppressed in most normal cells, whereas reactivated in more than 85% of human cancer cells [9,10]. In addition, the telomerase activity is regulated by telomeric repeat binding factor 1 (TRF1) and its associated proteins, including PinX1 [11]. PinX1 is a potent telomerase inhibitor and a putative tumor suppressor, firstly found as a Pin2/TRF1-binding protein [12]. However, unlike other TRF1-binding proteins, PinX1 is unique in that it can also directly bind to hTERT and inhibit telomerase activity [12].

PinX1 is a versatile gene at human chromosome 8p23, a region frequently associated with loss of heterozygosity (LOH) in a variety of human malignancies [13-15]. The full-length form of PinX1 is composed of 737 bp and encodes a 45-KDa nucleolar protein containing 328 amino acids [16]. It has been identified that Pinx1 deficiency could induce telomerase activation, telomere elongation and chromosome instability [17], whereas overexpression of PinX1 leads to a decrease in both telomerase activity and cancer cell tumorigenicity [18,19]. LOH of PinX1 resulted in gastric carcinoma development, which suggested PinX1 might have a potential inhibitory role in cancer metastasis [20]. Then increasing evidences demonstrate that PinX1 plays a key role as a putative tumor suppressor in human cancer progression [21-26]. However, the PinX1 expression status and its correlation with the clinicopathological features in breast cancer have never been investigated. In addition, the potential molecular mechanisms underlying the role of PinX1 in breast cancer are still unclear.

To evaluate the function of PinX1 in breast cancer, we used a tissue microarray (TMA) of human breast cancer patients and immunohistochemistry to analyze the correlation between PinX1 expression and clinicopathologic variables and patient survival. Furthermore, we demonstrated that PinX1 suppressed breast cancer migration and invasion by inhibiting the expression and activity of MMP-9 via NF-κB-dependent transcription in vitro and in vivo. These data suggested that PinX1 might be function as a tumor metastasis suppressor in the development and progression of breast cancer by regulating the NF-κB/MMP-9 signaling pathway, and might be a prognostic marker as well as a therapeutic target for breast cancer.

Results

Correlation of PinX1 staining with clinicopathologic parameters in breast cancer patients

To investigate PinX1 expression in breast cancer, immunohistochemistry was carried out in TMA slides (Figure 1A). Samples with IRS 0–3 and IRS 4–12 were classified as low and high expression of PinX1. Of the 405 breast cancer analyzed, low and high expression of PinX1 staining were 52.3% (212/405) and 47.7% (193/405), respectively (Table 1). We then analyzed the correlations between PinX1 expression and characteristics of the breast carcinomas, and found that PinX1 staining was dramatically decreased in histology grade II and III compared with histology grade I (P = 0.001, χ2 test, Table 1). We also found that PinX1 expression is significantly correlated with lymph node metastasis (P = 0.002, χ2 test, Table 1). However, we did not find any significant correlations between PinX1 expression and other clinicopathologic variables, including patient age, tumor size, ER status, PR status, HER2 status and p53 status.
Figure 1
Figure 1

Expression of PinX1 in breast cancer tissues and associated with 5-year overall and disease-specific survival in breast cancer patients. (A) Negative and positive staining in breast cancer tissue. Top panel, magnification × 200; bottom panel, magnification × 400. (B) Low PinX1 expression correlated with a poorer 5-year overall cumulative survival for 236 breast cancer patients (P = 0.010, log-rank test). (C) Low PinX1 expression correlated with a poorer 5-year disease-specific cumulative survival for 208 breast cancer patients (P = 0.003, log-rank test). Cum. indicates cumulative.

Table 1

PinX1 staining and clinicopathological characteristics of 405 breast cancer patients

Variables

PinX1 staining

Low (%)

High (%)

Total

P *

Age

    

≤50 years

99 (52.7)

89 (47.3)

188

0.906

>50 years

113 (52.1)

104 (47.9)

217

 

Tumor size

    

T1 (<2 cm)

47 (61.8)

29 (38.2)

76

0.090

T2 (2-5 cm)

148 (51.2)

141 (48.8)

289

 

T3 (>5 cm)

11 (39.3)

17 (60.7)

28

 

Lymph node metastasis

    

Negative

83 (43.5)

108 (56.5)

191

0.002

Positive

110 (59.5)

75 (40.5)

185

 

Histology grade

    

I

11 (30.6)

25 (69.4)

36

0.001

II

103 (50.5)

101 (49.5)

204

 

III

50 (68.5)

23 (31.5)

73

 

ER status

    

Negative

40 (54.8)

33 (45.2)

73

0.359

Positive

63 (48.1)

68 (51.9)

131

 

PR status

    

Negative

48 (54.5)

40 (45.5)

88

0.313

Positive

55 (47.4)

61 (52.6)

116

 

HER2 status

    

Negative

14 (66.7)

7 (33.3)

21

0.206

Positive

79 (52.0)

73 (48.0)

152

 

p53 status

    

Negative

41 (50.0)

41 (50.0)

82

0.347

Positive

52 (57.1)

39 (42.9)

91

 

* P values are from χ2 test.

Some cases were not available for the information.

PinX1 functions as an independent prognostic factor for human breast cancer

To further study whether PinX1 expression correlates with the survival of patients, Kaplan-Meier survival curves were constructed using 5-year overall and disease-specific cumulative survival to compare the patients with high PinX1 staining to those with low PinX1 staining (n = 236, follow-up time, 60 months). Our data revealed that low PinX1 staining correlated with both poorer overall and disease-specific patient survival (P = 0.010 and P = 0.003, respectively, log-rank test; Figure 1B & C). The 5-year overall cumulative survival rate dropped from 65.3% in patients with high PinX1 expression to 48.0% in those with low PinX1 expression, and the 5-year disease-specific cumulative survival rate dropped from 78.4% in patients with high PinX1 expression to 57.5% in those with low PinX1 expression.

Moreover, we examined whether PinX1 expression was an independent prognostic factor for breast cancer. The univariate Cox regression analyses revealed that PinX1 expression was an independent prognostic marker for breast cancer patients overall survival (hazard ratio, 0.573; 95% CI, 0.371-0.884; P = 0.012; Table  2 ) and disease-specific survival (hazard ratio, 0.417; 95% CI, 0.230-0.755; P = 0.004; Table  2 ). In multivariate Cox regression analysis, we found that PinX1 expression was also an independent prognostic marker for both 5-year overall survival (hazard ratio, 0.527; 95% CI, 0.404-0.656; P = 0.027; Table 3) and disease-specific survival (hazard ratio, 0.429; 95% CI, 0.222-0.630; P = 0.012; Table 3). Our results definitely confirmed that low PinX1 expression is associated with poor prognosis, suggesting that PinX1 may function as a prognostic marker for breast cancer.
Table 2

Univariate Cox proportional regression analysis on 5-year overall and disease-specific survival of 405 breast cancer patients

Variable *

Overall survival

Disease-specific survival

Hazard ratio

95% CI †

P *

Hazard ratio

95% CI †

P *

PinX1

      

Low

1.000

 

0.012

1.000

 

0.004

High

0.573

0.371-0.884

 

0.417

0.230-0.755

 

Age

      

≤50 years

1.000

 

0.443

1.000

 

0.630

>50 years

0.864

0.594-1.225

 

0.855

0.632-1.030

 

Tumor size

      

≤5 cm

1.000

 

0.002

1.000

 

0.000

>5 cm

2.289

1.363-3.843

 

3.463

2.730-3.935

 

Lymph node metastasis

      

Negative

1.000

 

0.000

1.000

 

0.000

positive

4.994

3.032-8.227

 

3.564

2.594-4.505

 

Histology Grade

      

I

1.000

 

0.002

1.000

 

0.005

II/III

2.309

1.740-3.456

 

2.554

1.618-3.551

 

* P values are from Log-rank test.

† CI: confidence interval.

Table 3

Multivariate Cox regression analysis on 5-year overall and disease-specific survival of 405 breast cancer patients

Variable *

Overall survival

Disease-specific survival

Hazard ratio

95% CI †

P

Hazard ratio

95% CI

P

PinX1

0.527

0.404 to 0.656

0.027

0.429

0.222 to 0.630

0.012

Age

0.993

0.740 to 1.345

0.836

0.856

0.652 to 1.222

0.884

Tumor size

2.730

1.947 to 3.785

0.003

2.913

1.882 to 4.146

0.001

Lymph node metastasis

3.183

1.911 to 4.505

0.001

3.962

2.975 to 4.756

0.000

Histology Grade

1.840

1.184 to 2.843

0.023

1.958

1.514 to 2.511

0.032

*Coding of variables: PinX1 was coded as 1 (low), and 2 (high). Age was coded as 1 (≤50 years), and 2 (>50 years). Tumor size was coded as 1 (≤5 cm), and 2 (>5 cm). Lymph node metastasis was coded as 1 (negative), and 2 (positive). Histology grade was coded as 1 (I), and 2 (II and III).

† CI: confidence interval.

PinX1 inhibits migration and invasion of human breast cancer cells in vitro

Because low PinX1 expression is associated with poor prognosis, supporting PinX1 may play important roles in one or more steps of tumor metastasis. We investigated the involvement of PinX1 in breast cancer cells migration and invasion. We transiently transfected MDA-MB-231 and BT-549 cells with control siRNA and PinX1 siRNA or pEGFP-C3 and pEGFP-C3-PinX1 plasmids, respectively. Forty-eight or twenty-four hours after transfection, PinX1 protein was significantly knockdown or overexpressed in cancer cells, respectively (Figure 2A & B). In cell migration assay, we found that the ability of cell migration was drastically increased after PinX1 knockdown in both MDA-MB-231 and BT-549 cell line (Figure 2C). In contrast, overexpression of PinX1 inhibited cell migration (Figure 2D). Meanwhile, the results of the cell invasion assay corresponded with the cell migration assay (Figure 2E & F). However, overexpression or knockdown of PinX1 had no detectable effect on the proliferation of breast cancer cells under normal culture conditions (data not shown).
Figure 2
Figure 2

PinX1 inhibits migration and invasion of human breast cancer cells. (A) Western blot analysis of the relative protein level of PinX1 in PinX1 knockdown (siPinX1) and control siRNA (siCtrl) groups for both MDA-MB-231 and BT-549 cell lines. (B) Western blot analysis of the relative protein level of PinX1 in PinX1 overexpression (PinX1OE) and control vector (Vector) groups for both MDA-MB-231 and BT-549 cell lines. (C) and (E) PinX1 knockdown significantly inhibited migration and invasion abilities of MDA-MB-231 and BT-549 cells. (D) and (F) PinX1 overexpression significantly inhibited migration and invasion abilities of MDA-MB-231 and BT-549 cells. All experiments were carried out in triplicate. Data are shown as means ± SD. ***, P < 0.001.

PinX1 inhibits human breast cancer cells’ migration and invasion abilities by suppressing MMP-9 expression and activity

To investigate the mechanisms of PinX1 regulating migration and invasion in breast cancer cells, we performed western blot to detect the MMPs protein levels and gelatin zymography to observe the MMPs activity. Our result showed that the MMP-9 expression and activity were negatively regulated by PinX1 in MDA-MB-231 and BT-549 cells,but not MMP-2 (Figure 3A & B & C). So we supposed PinX1 suppress migration and invasion of breast cancer cells by regulating MMP-9 expression and activity. To further validate our assumption, we added MMP-9 inhibitor I (sc-311437, Santa Cruz) at the same time of PinX1 siRNA transfecting into cells. As expected, the upregulation of MMP-9 was blocked by MMP-9 inhibitor I (Figure 3D & E). We also validated this hypothesis by migration and invasion analysis, the migration and invasion ability can be enhanced by knocking down PinX1 in MDA-MB-231 and BT-549 cells, nevertheless, these regulations were blocked by MMP-9 inhibitor I (Figure 3F & G).
Figure 3
Figure 3

PinX1 inhibits migration and invasion of breast cancer cells by suppressing MMP-9 expression and activity. (A) Western blot analysis of the relative protein levels of PinX1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in PinX1 siRNA and control siRNA group for both MDAMB-231 and BT-549 cell lines. (B) Western blot analysis of the relative protein levels of PinX1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in PinX1OE and Vector groups for both MDA-MB-231 and BT-549 cell lines. (C) Top panel, gelatin zymography analysis of the relative enzyme activities of MMP-9 in PinX1 knockdown and control siRNA group for both MDA-MB-231 and BT-549 cell lines. Bottom panel, gelatin zymography analysis of the relative enzyme activities of MMP-9 in PinX1OE and Vector groups for both MDA-MB-231 and BT-549 cell lines. (D) Western blotting of PinX1 and MMP-9 in there groups of control siRNA, PinX1 siRNA, and PinX1 siRNA co-treated with MMP-9 inhibitor I for both MDA-MB-231 and BT-549 cell lines. (E) Gelatin zymography analysis of MMP-9 in there groups of control siRNA, PinX1 siRNA, and PinX1 siRNA co-treated with MMP-9 inhibitor I for both MDA-MB-231 and BT-549 cell lines. (F) and (G) The increased abilities of migration and invasion regulated by PinX1 knockdown in breast cancer cells was blocked by MMP-9 inhibitor I. All experiments were carried out in triplicate. Histograms represent means ± SD. ***, P < 0.001.

As we know TIMP-1 and TIMP-2 is the tissue inhibitor of MMP-9 and MMP-2, so we detected the expression of TIMP protein. Our data showed that MMP-9 expression was up-regulated or down-regulated corresponded with PinX1 knockdown or overexpression, however, the expression of TIMP-1 had not changed correspondingly. Moreover, neither overexpressing nor silencing PinX1 had any effect on the protein levels of MMP-2 and TIMP-2 (Figure 3A & B).

PinX1 suppress MMP-9 expression via NF-κB-dependent transcription

Furthermore, increasing evidence demonstrate that several MMPs (including MMP-9) expression and activation were regulated by NF-κB activation in many human cancers [27,28]. G-patch domain of PinX1 is also an important nucleic acids binding domain which could combine with the C-terminus of the NF-κB-repression factor (NRF) [29]. Thus, PinX1 may also inhibit the transcriptional activity of NF-κB proteins by direct protein-protein interaction with its G-patch domain. Western blot results showed that the level of NF-κB-p65 protein was dramatically increased in PinX1KD-MDA-MB-231 cells and PinX1KD-BT-549 cells. In contrast, NF-κB-p65 expression was down-regulated sharply in PinX1OE-MDA-MB-231 cells and PinX1OE-BT-549 cells (Figure 4A & B). To further confirm whether PinX1 regulated MMP-9 expression via the NF-κB signaling pathway in human breast cancer cells, we transfected NF-κB-p65 siRNA (Santa Cruz) into PinX1KD-MDA-MB-231 cells and PinX1KD-BT-549 cells. Our result indicated that the MMP-9 expression was up-regulated in PinX1KD-MDA-MB-231 cells and PinX1KD-BT-549 cells, but these effects were further blocked by silencing NF-κB-p65 with the specific siRNA (Figure 4A & B). These data provide definite evidence that PinX1 may modulate MMP-9 expression by NF-κB transcription factor.
Figure 4
Figure 4

PinX1 suppress MMP-9 expression via NF-κB-dependent transcription. (A) and (B) Western blot analysis of the relative protein levels of PinX1, MMP-9 and NF-κB-p65 in four groups of control, PinX1OE , PinX1KD and PinX1KD co-treated with NF-κB-p65 siRNA for both MDA-MB-231 and BT-549 stable cell lines. The NF-κB specific siRNA dramatically prevented the up-regulation of MMP-9 expression induced by PinX1 knockdown. (C) and (D) The increased ability of migration and invasion regulated by PinX1 knockdown was suppressed by NF-κB-p65 siRNA in both MDA-MB-231 and BT-549 stable cell lines. All experiments were carried out in triplicate. Histograms represent means ± SD. ***, P < 0.001.

We also validated the mechanism by migration and invasion analysis. The migration and invasion ability can be enhanced in PinX1KD-MDA-MB-231 cells and PinX1KD-BT-549 cells, however, these effects were dramatically reversed by treatment with NF-κB-p65 siRNA (Figure 4C & D). These data suggested that PinX1 may regulate the migration and invasion via the NF-κB/MMP-9 signaling pathway.

PinX1 inhibits breast cancer cells metastasis in vivo

Lastly, we examined whether PinX1 suppressed breast cancer metastasis in vivo. PinX1OE-MDA-MB-231, PinX1KD-MDA-MB-231 and Ctrl-MDA-MB-231 cell lines were established previously. After 3 weeks selection following with lentivirus infection, the PinX1 protein levels of these cell lines were confirmed by western blot. Then continuing to incubate them without adding puromycin for 2 months, we determined that the PinX1 protein expression levels of three stable cell lines had not been changed (Figure 5A).
Figure 5
Figure 5

PinX1 inhibits breast cancer cells metastasis in vivo. (A) Left panel, Western blotting of PinX1 in there groups of Ctrl-MDA-MB-231 cell lines, PinX1OE-MDA-MB-231 cell lines and PinX1KD-MDA-MB-231 cell lines, which was selected with puromycin for 2 weeks after lentivirus infection. Right panel, without puromycin selection for 2 months, PinX1 expression levels were not changed in MDA-MB-231 stable cell lines. (B) H&E staining sections of lungs 2 months after injection of PinX1KD-MDA-MB-231 cell lines in BALB/c nude mouse through tail vein. Left panel, magnification × 100; right panel, magnification × 400. (C) Representative images of 10% buffered formalin fixed lungs with metastatic nodules 2 months after injection of Ctrl, PinX1OE and PinX1KD MDA-MB-231 stable cell lines. Arrows indicate metastatic nodules. (D) The number of lung metastatic nodules was counted under a dissecting microscope. Compared with the PinX1OE group, a statistically dramatic increase in the number of the lung metastases was seen in PinX1KD group, and these two groups also had significant diversity compared with Ctrl group respectively. Data are displayed with means ± SD from 10 mice in each group. ***, P < 0.001.

The BALB/c nude mice were randomly divided into three groups: PinX1OE, PinX1KD and Control group, each group consisted of 10 mice. Three groups of nude mice were injected through tail vein with PinX1OE-MDA-MB-231, PinX1KD-MDA-MB-231 and Ctrl-MDA-MB-231 cells respectively. After 2 months, three groups of mice were sacrificed and their lungs were resected and fixed in 10% buffered formalin for metastatic nodules counting and further histopathological analysis. Randomly selected metastatic nodules had been validated by H&E staining (Figure 5B). Extensive tumor formation was found in PinX1KD group. In contrast, the lungs in PinX1OE group had fewer and smaller detectable tumor nodules (Figure 5C). Compared with PinX1OE group, the dramatic increase in the number of the tumor nodules was observed in PinX1KD group, meanwhile, PinX1OE group and PinX1KD group had significant differences compared with Control group respectively (Figure 5D).

Discussion

PinX1 is a functional gene at human chromosome 8p23, a region frequently associated with loss of heterozygosity (LOH) in a variety of human malignancies [13]. Increasing evidence demonstrate that PinX1 plays a key role as a putative tumor suppressor in human cancer progression [18,19]. However, the expression and function of PinX1 in breast cancer and its correlation with the clinicopathological features of breast cancer patients have never been investigated.

In the present study, we used a breast cancer TMA containing 405 tumor samples with specific clinical data to investigate the role of PinX1 in human breast cancer. Our data showed that low PinX1 expression was associated with lymph node metastasis and histology grade in patients, as well as with poorer overall and disease-specific survival (Figure 1B & C; Table 1). Cox regression analysis revealed that low PinX1 expression was an independent negative prognostic indicator for breast cancer patients (Table  2 ; Table 3). These findings suggested a potential role of PinX1 in regulating breast cancer metastasis and functioning as a breast cancer candidate clinical prognostic marker. Our clinical data urged us to carry out a series of in vitro and in vivo experiments to explore the potential mechanisms.

The matrix metalloproteinase (MMP) family can degrade the extracellular matrix (ECM) in the major early stages of a number of malignant tumors, which plays an important role in cancer invasion and metastasis [30]. High expression of MMP-9 and MMP-2 were associated with lymph node metastasis as well as with poorer survival in breast cancer [31]. Our data demonstrated that PinX1 inhibited breast cancer cells’ migration and invasion abilities by down-regulating MMP-9 expression and activity in vitro (Figure 2; Figure 3). MMPs activity is controlled by specific, endogenous tissue inhibitors of metalloproteinases (TIMPs), and the imbalance between MMPs and TIMPs is responsible for cancer metastasis [32]. TIMP-1 is the tissue inhibitor of MMP-9, which negatively regulating MMP-9 enzyme activity were involved in several tumor metastasis processes, including breast cancer [33]. But in our study, TIMP-1 expression was not seemed to be the regulator of MMP-9 activation in breast cancer cells (Figure 3A & B). These result suggested us to investigate the potential mechanism of how PinX1 regulates MMP-9 expression and activity.

NF-κB is a critical transcription factor activated in various types of human cancers and plays a crucial role in tumor development and progression [34,35]. The NF-κB signaling modulates several key biological processes during the development and progression of cancer by inducing transcription of a variety of target genes that regulate cell proliferation, survival, invasion and angiogenesis [36-38]. NF-κB is constitutively present in cells as a heterodimer, consisting of a p50 DNA-binding subunit and a p65 transactivating subunit [39]. Furthermore, increasing evidence demonstrate that MMP-9 expression and activation were regulated by p65 up-regulation and nuclear translocation which induced NF-κB activation in many human cancers [27,28]. Our data indicated that the NF-κB specific siRNA dramatically prevented the up-regulation of MMP-9 expression induced by PinX1 knockdown (Figure 4A & B). Consistently, the increased ability of migration and invasion induced by PinX1 knockdown was also suppressed by inhibition of NF-κB-p65 expression in breast cancer cells (Figure 4C & D). Thus, these results suggested that PinX1 may regulate the migration and invasion via the NF-κB/MMP-9 signaling pathway.

We regret to investigate the potential regulation mechanism between PinX1 and NF-κB pathway, however, we have found some conceivable relations between them. Human PinX1 protein contains an N-terminal Gly-rich patch (G-patch) and a C-terminal TID (telomerase inhibitory domain) [12]. G-patch domain existed in a number of putative RNA-binding proteins involved in tumor suppression and DNA-damage repair [40], but the function of them had been researched rarely. Moreover, G-patch domain of PinX1 is also an important nucleic acids binding domain which could combine with the C-terminus of the NF-κB-repression factor (NRF) [29]. NRF is a nuclear inhibitor of NF-κB, which can inhibit the transcriptional activity of NF-κB proteins by direct protein-protein interaction [41]. Thus, we conclude that PinX1 also can inhibit the transcriptional activity of NF-κB proteins by direct protein-protein interaction with its G-patch domain (Figure 6). These hypothesizes have never been definitely validated. However, the association between PinX1 and NF-κB in breast cancer cells exists indeed. So we will investigate the further molecular mechanisms between PinX1 and NF-κB signaling pathway continually.
Figure 6
Figure 6

A Model of PinX1 suppresses MMP-9 expression via NF-κB signaling pathway. We speculate that PinX1 can suppress the expression of MMP-9 owing to the inhibition of transcriptional activity of NF-κB p65 proteins by direct protein-protein interaction with its G-patch domain which could combine with the C-terminus of the NF-κB-repression factor (NRF).

To further observe the functional role of PinX1 in breast cancer metastasis in vivo, three groups of nude mice experimental model were constructed. We investigated that PinX1 overexpression in breast cancer cells significantly inhibited the formation of metastasis nodules in lung of nude mice. In contrast, PinX1 knockdown dramatically enhanced the metastasis process (Figure 5).

In conclusion, loss of PinX1 expression was significantly correlated with breast cancer progression and was an independent negative prognostic factor in breast cancer patients. PinX1 suppressed breast cancer migration and invasion by inhibiting the expression and activity of MMP-9 via NF-κB-dependent transcription. Therefore PinX1 may be an attractive therapeutic target for the treatment of breast cancer.

Materials and methods

Patient specimens and tissue microarray construction

The collection of patient specimens and construction of the tissue microarray (TMA) have been previously described [42]. The study material consists of a series of 405 consecutive cases of primary breast carcinoma, from The First Affiliated Hospital of Nanjing Medical University, between 1996 and 2005. All these patients were treated with surgery only or with postoperative adjuvant therapy. The patients’ clinicopathologic information including age at diagnosis, tumor size, histology grade, lymph node metastasis, ER status, PR status, HER2 status and p53 status was obtained from the archive of the pathology department and confirmed by the medical record of the hospital. The histologic grade was assessed using Bloom-Richardson classification. Five-year clinical follow-up results were available for 236 patients. The use of these tissue specimens was approved by the Ethics Committee of the Hospital.

Immunohistochemistry of TMA

Immunohistochemistry was carried out as described before [43]. According to the streptavidin-peroxidase (Sp) method using a standard Sp Kit (Zhongshan biotech, Beijing, China). The TMA slides were dewaxed at 60°C for 20 min followed by three 5-min washes with xylene. The tissues were then rehydrated by washing the slides for 5-min each with 100%, 95%, 80% ethanol and finally with distilled water. The slides were then heated to 95°C for 30 min in 10 mmol/L sodium citrate (pH 6.0) for antigen retrieval and then treated with 3% hydrogen peroxide for 1 hour to block the endogenous peroxidase activity. Then subsequently the TMA slides were incubated with a polyclonal rabbit anti-PinX1 antibody (1:50 dilution; Novus Biologicals, Littleton, CO, USA) at 4°C overnight, and 3, 3′-diaminobenzidine (DAB; Zhongshan Biotech, Beijing, China) was used to produce a brown precipitate. Negative controls were performed by substituting primary antibodies with non-immune serum.

Evaluation of immunostaining

The evaluation of PinX1 staining was blindly and independently examined by two pathologists. Positive PinX1 immunostaining is defined mainly in the nucleus area and also can be observed in the cytoplasm. We grade it according to both the intensity and percentage of cells with positive staining. The PinX1 staining intensity was scored 0 to 3 (0 = negative; 1 = weak; 2 = moderate; 3 = strong). The percentage of PinX1-positive stained cells was also scored into four categories: 1 (0%-25%), 2 (26%-50%), 3 (51%-75%) and 4 (76%-100%). The level of PinX1 staining was evaluated by the immunoreactive score (IRS), which is calculated by multiplying the scores of staining intensity and the percentage of positive cells. Based on the IRS, the PinX1 staining pattern was categorized as negative (IRS: 0), weak (IRS: 1–3), moderate (IRS: 4–6) and strong (IRS: 8–12). The concordance for IRS staining score of PinX1 between the two pathologists was 363 in 405 samples (90%), and the few discrepancies were resolved by consensus using a multihead microscope.

The optimum cutoff value of IRS was obtained by receiver-operator characteristic analysis, and the areas under the curves at different cutoff values of the PinX1 IRS for 1, 3 and 5 years of overall survival time were also calculated. The optimum value of cutoff point of the PinX1 IRS was shown to be 3 since it had the best predictive value for survival (Additional file 1: Figure S1). Under these conditions, samples with IRS 0–3 and 4–12 were classified as having low or high expression of PinX1, respectively.

Animals and cell lines

Female BALB/c nude mice, 6 weeks old, were purchased from the Shanghai Laboratory Animal Center (Shanghai, China) for studies approved by the Animal Care Committee of Xuzhou Medical College. Two human breast cancer cell lines MDA-MB-231 and BT-549 were purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). MDA-MB-231 cells were cultured in Leibovitz’ s L-15 Medium (Gibco, USA) supplemented with 10% fetal calf serum (Gibco, USA), BT-549 cells were cultured in RPMI 1640 Medium (Invitrogen, Shanghai, China) supplemented with 10% fetal calf serum. These two cells were both incubated in a 37°C humidified incubator with 5% CO2.

siRNA and DNA transfections, and stable cell line generation

Cells were grown to 50% confluence before small interfering RNA (siRNA) transfection. PinX1 siRNA (GenePharma, Shanghai, China), NF-κB-p65 siRNA (Santa Cruz, CA, USA) or Nonspecific control siRNA (GenePharma, Shanghai, China) was transfected by siLentFect Lipid Reagent (Bio-Rad, CA, USA) according to the manufacturer’s protocol. The pEGFP-C3 and pEGFP-C3-PinX1 expression plasmids were obtained from Dr Xiao-Fen Lai (Southern Medical University, Guangzhou, China). Transfection of the pEGFP-C3-PinX1 plasmid and the pEGFP-C3 vector into the MDA-MB-231 and BT-549 cells were carried out using Lipofectamine 2000 transfection reagent (Invitrogen) following the manufacturer’s instructions.

PinX1 overexpression MDA-MB-231 cell lines (PinX1OE-MDA-MB-231), PinX1 knockdown MDA-MB-231 cell lines (PinX1KD-MDA-MB-231) and control MDA-MB-231 cell lines (Ctrl-MDA-MB-231) were established by infecting with lentivirus packing PinX1 expression vector, PinX1 shRNA expression vector and control vector respectively (GenePharma, Shanghai, China). It is the same as the construction of PinX1 overexpression BT-549 cell lines (PinX1OE-BT-549), PinX1 knockdown BT-549 cell lines (PinX1KD-BT-549) and control BT-549 cell lines (Ctrl-BT-549). Target cells were infected with lentivirus for 48 hours then selected with puromycin (Santa Cruz) for three weeks.

Western blot analysis

Western blot analysis was performed as described previousely [44]. The following antibodies were used for western blot: rabbit anti-PinX1 (Novus Biologicals); rabbit anti-MMP-2, anti-MMP-9, anti-TIMP-1, anti-TIMP-2 (all from Cell Signaling Technology); rabbit anti-NF-κB-p65 (Santa Cruz Biotechnology); mouse anti-β-actin (Cell Signaling Technology); Infrared IRDye-labeled secondary antibody (LI-COR, NE, USA) was applied to the blot for 2 hour at room temperature, the signals were detected with Odyssey Infrared Imaging system (LI-COR).

Cell migration and invasion assay

Cell migration and invasion assay were performed using modified two-chamber plates with a pore size of 8 μm. The transwell filter coating with or without Matrigel (BD Biosciences, Mississauga, Canada) were used respectively for invasion and migration assay. The detailed conditions were described previously [45].

Gelatin zymography

Gelatin zymography was performed as described before [46]. Thirty-six hours after transfection, cells were incubated in serum-free medium for 24 h. The proteins in the conditioned medium were concentrated with Amicon Ultra-4-30 k centrifugal filters (Millipore, MA, USA) at 7500 g for 20 min at 4°C. Fifty micrograms of the proteins were loaded on a 10% polyacrylamide gel containing 0.1% gelatin (Sigma, MO, USA). Gelatinolytic activity was shown as clear areas in the gel. Gels were photographed and then quantitatively measured by scanning densitometry.

Tail vein assay of metastasis

The BALB/c nude mice were randomly divided into three groups: PinX1OE, PinX1KD and Control group, each group consisted of 10 mice. The mice were injected intravenously with 2.5 × 106 MDA-MB-231 cells in 200 μl of PBS through tail vein. After 2 months, the three groups of mice were sacrificed, their lungs were resected and fixed in 10% buffered formalin for metastatic nodules counting and further histopathological analysis. The number of metastatic nodules presented on the surface of each group of lungs was counted by visual inspection using a stereoscopic dissecting microscope.

Statistical analysis

For the TMA, statistical analysis was performed with SPSS 20 software (SPSS, Inc, Chicago, IL). The association between PinX1 staining and the clinicopathologic parameters of the breast cancer patients was evaluated by χ2 test. The Kaplan-Meier method and log-rank test were used to evaluate the correlation between PinX1 expression and patient survival. Cox regression model was used for multivariate analysis. Data are expressed as the means ± SD. Two-factor analysis of variance procedures and the Dunnett’s t-test were used to assess differences within treatment groups. Differences were considered significant when P < 0.05.

Notes

Abbreviations

PinX1: 

PIN2/TRF1-interacting telomerase inhibitor 1

hTERT: 

Human telomerase reverse transcriptase

TRF1: 

Telomeric repeat binding factor 1

LOH: 

Loss of heterozygosity

MMP: 

Matrix metalloproteinase

TIMPs: 

The specific, endogenous tissue inhibitors of metalloproteinases

TID: 

Telomerase inhibitory domain

NRF: 

The NF-κB-repression factor

ECM: 

The extracellular matrix

TMA: 

The tissue microarray

IRS: 

The immunoreactive score

Declarations

Acknowledgements

This project is supported by grants from the National Natural Science Foundation of China (No.81472663, 81201636), the Science and Technology Department of Jiangsu Province (No.BK2012139), and China Postdoctoral Science Foundation (No. 2014 T70549, 2012 M511323).

Authors’ Affiliations

(1)
Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, 84 West Huaihai Road, Xuzhou, 221002, Jiangsu Province, China
(2)
School of Medical Imaging, Xuzhou Medical College, Xuzhou, Jiangsu, China
(3)
Department of Pathology, Xuzhou Medical College, Xuzhou, Jiangsu, China
(4)
Department of Urology, the Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
(5)
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

References

  1. Wang X, Lu H, Urvalek AM, Li T, Yu L, Lamar J, et al. KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene. 2011;30:1901–11.View ArticlePubMed CentralPubMedGoogle Scholar
  2. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics. CA Cancer J Clin. 2011;61:409–18.View ArticlePubMedGoogle Scholar
  3. Chen J, Gallo KA. MLK3 regulates paxillin phosphorylation in chemokine-mediated breast cancer cell migration and invasion to drive metastasis. Cancer Res. 2012;72:4130–40.View ArticlePubMedGoogle Scholar
  4. Cowper-Sal Lari R, Zhang X, Wright JB, Bailey SD, Cole MD, Eeckhoute J, et al. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet. 2012;44:1191–8.View ArticlePubMed CentralPubMedGoogle Scholar
  5. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2:257–65.View ArticlePubMedGoogle Scholar
  6. Dong CK, Masutomi K, Hahn WC. Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol. 2005;54:85–93.View ArticlePubMedGoogle Scholar
  7. Smogorzewska A, de Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem. 2004;73:177–208.View ArticlePubMedGoogle Scholar
  8. Lin SY, Elledge SJ. Multiple tumor suppressor pathways negatively regulate telomerase. Cell. 2003;113:881–9.View ArticlePubMedGoogle Scholar
  9. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.View ArticlePubMedGoogle Scholar
  10. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S A. 1995;92:9082–6.View ArticlePubMed CentralPubMedGoogle Scholar
  11. Lee TH, Tun-Kyi A, Shi R, Lim J, Soohoo C, Finn G, et al. Essential role of Pin1 in the regulation of TRF1 stability and telomere maintenance. Nat Cell Biol. 2009;11:97–105.View ArticlePubMed CentralPubMedGoogle Scholar
  12. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell. 2001;107:347–59.View ArticlePubMedGoogle Scholar
  13. Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H, Croce CM. Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Clin Cancer Res. 2000;6:1372–7.PubMedGoogle Scholar
  14. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics. 1996;35:46–54.View ArticlePubMedGoogle Scholar
  15. Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, et al. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol. 1996;122:585–9.View ArticlePubMedGoogle Scholar
  16. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics. 1996;35:55–65.View ArticlePubMedGoogle Scholar
  17. Zhang B, Bai YX, Ma HH, Feng F, Jin R, Wang ZL. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res. 2009;69:75–83.View ArticlePubMedGoogle Scholar
  18. Zhou XZ, Huang PY, Shi R, Lee TH, Lu GN, Zhang ZH, et al. The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. J Clin Invest. 2011;121:1266–82.View ArticlePubMed CentralPubMedGoogle Scholar
  19. Zhou XZ. PinX1: a sought-after major tumor suppressor at human chromosome 8p23. Oncotarget. 2011;2:810–9.PubMed CentralPubMedGoogle Scholar
  20. Ma YY, Wu L, Liu C, Xu L, Li D, Li JC. The correlation of genetic instability of PINX1 gene to clinico-pathological features of gastric cancer in the Chinese population. J Cancer Res Clin Oncol. 2009;135:431–7.View ArticlePubMedGoogle Scholar
  21. Shi R, Zhao Z, Zhou H, Wei M, Ma WL, Zhou JY, et al. Reduced expression of PinX1 correlates to progressive features in patients with prostate cancer. Cancer Cell Int. 2014;14:46.View ArticlePubMed CentralPubMedGoogle Scholar
  22. Zuo J, Wang DH, Zhang YJ, Liu L, Liu FL, Liu W. Expression and mechanism of PinX1 and telomerase activity in the carcinogenesis of esophageal epithelial cells. Oncol Rep. 2013;30:1823–31.PubMedGoogle Scholar
  23. Liu JY, Qian D, He LR, Li YH, Liao YJ, Mai SJ, et al. PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway. Mol Cancer. 2013;12:148.View ArticlePubMed CentralPubMedGoogle Scholar
  24. Lai XF, Shen CX, Wen Z, Qian YH, Yu CS, Wang JQ, et al. PinX1 regulation of telomerase activity and apoptosis in nasopharyngeal carcinoma cells. J Exp Clin Cancer Res. 2012;31:12.View ArticlePubMed CentralPubMedGoogle Scholar
  25. Zhang L, Jiang Y, Zheng Y, Zeng Y, Yang Z, Huang G, et al. Selective killing of Burkitt’s lymphoma cells by mBAFF-targeted delivery of PinX1. Leukemia. 2011;25:331–40.View ArticlePubMed CentralPubMedGoogle Scholar
  26. Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY, et al. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci. 2010;101:1543–9.View ArticlePubMedGoogle Scholar
  27. Shih YW, Chien ST, Chen PS, Lee JH, Wu SH, Yin LT. Alpha-mangostin suppresses phorbol 12-myristate 13-acetate-induced MMP-2/MMP-9 expressions via alphavbeta3 integrin/FAK/ERK and NF-kappaB signaling pathway in human lung adenocarcinoma A549 cells. Cell Biochem Biophys. 2010;58:31–44.View ArticlePubMedGoogle Scholar
  28. Fukuyama R, Ng KP, Cicek M, Kelleher C, Niculaita R, Casey G, et al. Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Mol Carcinog. 2007;46:402–13.View ArticlePubMedGoogle Scholar
  29. Jianfeng D, Feng J, Chaoneng J, Zhongzhou Z, Shaohua G, Qihan W, et al. Cloning of the correct full length cDNA of NF-kappaB-repressing factor. Mol Cells. 2003;16:397–401.PubMedGoogle Scholar
  30. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9–34.View ArticlePubMedGoogle Scholar
  31. Li HC, Cao DC, Liu Y. Prognostic value of matrix metalloproteinases (MMP2 and MMP9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004;88:75–85.View ArticlePubMedGoogle Scholar
  32. Giannelli G, Erriquez R, Fransvea E, Daniele A, Trerotoli P, Schittulli F, et al. Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer. 2004;109:782–5.View ArticlePubMedGoogle Scholar
  33. Jinga DC, Blidaru A, Condrea I. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006;10:499–510.View ArticlePubMedGoogle Scholar
  34. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.View ArticlePubMedGoogle Scholar
  35. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.View ArticlePubMedGoogle Scholar
  36. Kim YR, Kim IJ, Kang TW, Choi C, Kim KK, Kim MS, et al. HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis. Oncogene. 2014;33:4558–67.View ArticlePubMedGoogle Scholar
  37. Jiang L, Lin C, Song L, Wu J, Chen B, Ying Z, et al. MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-kappaB/IkappaBalpha negative feedback loop. J Clin Invest. 2012;122:33–47.View ArticlePubMed CentralPubMedGoogle Scholar
  38. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008;18:19–26.View ArticlePubMed CentralPubMedGoogle Scholar
  39. Lee WR, Chung CL, Hsiao CJ, Chou YC, Hsueh PJ, Yang PC, et al. Suppression of matrix metalloproteinase-9 expression by andrographolide in human monocytic THP-1 cells via inhibition of NF-κB activation. Phytomedicine. 2012;19:270–7.View ArticlePubMedGoogle Scholar
  40. Aravind L, Koonin EV. G-patch: a new conserved domain in eukaryotic RNA-processing proteins and type D retroviral polyproteins. Trends Biochem Sci. 1999;24:342–4.View ArticlePubMedGoogle Scholar
  41. Nourbakhsh M, Oumard A, Schwarzer M, Hauser H. NRF, a nuclear inhibitor of NF-kappaB proteins silencing interferon-beta promoter. Eur Cytokine Netw. 2000;11:500–1.PubMedGoogle Scholar
  42. Bai J, Yong HM, Chen FF, Mei PJ, Liu H, Li C, et al. Cullin1 is a novel marker of poor prognosis and a potential therapeutic target in human breast cancer. Ann Oncol. 2013;24:2016–22.View ArticlePubMedGoogle Scholar
  43. Bai J, Mei PJ, Liu H, Li C, Li W, Wu YP, et al. BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro. J Cancer Res Clin Oncol. 2012;138:991–8.View ArticlePubMedGoogle Scholar
  44. Bai J, Zhou Y, Chen GD, Zeng JY, Ding JJ, Tan YF, et al. Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 2011;42:375–83.View ArticlePubMedGoogle Scholar
  45. Chen FF, Bai J, Li W, Mei PJ, Liu H, Li LL, et al. RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. PLoS One. 2013;8:e56241.View ArticlePubMed CentralPubMedGoogle Scholar
  46. Bai J, Zhang J, Wu J, Shen L, Zeng J, Ding J, et al. JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene. 2010;29:1227–37.View ArticlePubMedGoogle Scholar

Copyright

© Shi et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

Molecular Cancer

ISSN: 1476-4598